We undertook a prospective, randomized open comparison of the broad-spectrum cephalosporins cefepime and ceftazidime in treatment of hospitalized subjects with skin or wound infections and complicated nosocomial urinary tract infections. Cefepime treatment (dosage, 2.0 g intravenously twice daily for 4 to 28 days) was successful in 36 (90%) of 40 infections of the skin and skin structure or wounds and in 16 (84%) of 19 nosocomial urinary tract infections. Ceftazidime treatment, 2.0 g every 8 h, was successful in 34 (96%) of 36 infections of the skin and skin structure and in 15 (88%) of 17 urinary tract infections. Microbiological eradication rates of each agent overall and for Pseudomonas aeruginosa were greater than 90%. In the cefepime group, one death occurred, contributed to by an enterococcal superinfection acquired during study drug therapy, and there were two mild and transient adverse experiences observed. Cefepime was comparable to ceftazidime in treatment of infections of the skin and skin structure requiring hospitalization and of complicated nosocomial urinary tract infections.
broad-spectrum cephalosporins against multiply resistant strains of the family Enterobacteriaceae. (3, (5) (6) (7) ; these pathogens tend to be overwhelming producers of P-lactamases, for which cefepime has a low affinity and is resistant to hydrolysis. We undertook an open, randomized comparison of cefepime and ceftazidime in treatment of bacterial infections of the skin and skin structures and urinary tract in hospitalized subjects.
MATERIALS AND METHPDS
Eligible patients for study enrollment included adults hospitalized in St. Luke's Episcopa} Hospital, Houston, Tex., or Hospital Mexico, Sgn Jose, Costa Rica, with culture-proven infections due to bacteria susceptible to both cefepime and ceftazidime. Included were infections of the skin or skin structures which reqijired hospitalization for therapy and complicated nosocomial infections of the urinary' tract which required antibiotic therapy because of fever, positive cultures, and the ahsence of another identified source of infection. fpr the -purposes of this study, ("complicated" was definedto be jhe presence of an indwelling catheter or obstructive uropathy. Exclusion criteria included pregnancy or laCtation, history of serious penicillin or cephalosporin hypersensjtivitj, anuria or a need for dialysis, granulocyte count:'of less than 500 mm3, human immunodeficiency virus seropositivity or the presence of a terminal illness, and the likelillood of concomitant or extended (greater than 28 days) regimens of antibiotics (espe-* Corresponding author.
cially patients with burns, vascular or orthopedic prostheses, or possible osteomyelitis).
As originally approved by the Institutional Review Board of Baylor College of Medicine, this protocol was designed to include eligible subjects with pneumonia and/or bacteremia as well. During the time period of this study, however, we experienced competition with other departments for eligible patients with these infections, and thus enrollment was restricted.
Informed consent was provided. Enrolled subjects provided a medical history and were examined. The following types of laboratory studies were performed: hematology (hemoglobin, hematocrit, leukocyte count, platelet count, erythrocyte sedimentation rate, prothrombin'time, and partial thromboplastin time), serum chemistries (serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, total bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine, glucose, sodium, potassium, calcium, and phosphorous), and urinalysis (specific gravity, pH, albumin, glucose, and microscopic examination). Prior to drug therapy, all abscesses were drained and any necessary debridement to ensure adequate tissue healing was done. Cultures were taken from the site of infection,'blood cultures were performed if bacteremia was suspected, and anaerobic cultpres were performed if the clinical criteria for anaerobic qacterial infection were present. For skin or wound infections, specimens were obtained by aspiration or deep swab. Those bacteria originally isolated from skin or soft tissues were considered to be pathogenic. Quantitative urine cul- tures were performed, with >100,000 CFU of an organism per ml defined as significant. Under this protocol we made no distinction between superinfection and colonization in terms of reporting, although study drug therapy was to be discontinued in the presence of resistant organisms determined to be pathogenic. Study drug therapy was continued for superinfections if the organisms were susceptible in vitro to the study drug or if in the opinion of the investigator and the microbiology laboratory any new resistant organisms bAll new organisms isolated during study drug therapy. were not causing infection, as might be the case with rare enterococci, anaerobes, or fungi.
All bacteria isolated during the study were tested for susceptibility to cefepime and ceftazidime. Organisms were defined as susceptible to cefepime when the MIC was -8 ,ug/ml or the zone diameter resulting from a 30-,ug disk was .19 mm, as moderately susceptible to cefepime when the MIC was 16 jig/ml or the zone diameter was 16 to 18 mm, or as resistant to cefepime when the MIC was .32 ,ug/ml or the zone diameter was <15 mm. Standard susceptibility criteria for ceftazidime were used. Organisms were defined as susceptible to ceftazidime when the MIC was c8 ,ug/ml or the zone diameter resulting from a 30-,ug disk was .18 mm, as moderately susceptible to cefepime when the zone diameter was 15 to 17 mm, or as resistant to cefepime when the MIC was >16 ,ug/ml or the zone diameter was 14 mm.
Cefepime was given as 2.0 g intravenously every 12 h (ql2h), while ceftazidime was given as 2.0 g intravenously q8h. Concentrations of the study drugs in serum were not measured. The study protocol permitted a reduction in dosages in cases of impaired renal function. For cefepime, the adjusted dosage was 2.0 g q24h for subjects with creatinine clearance (CC) of 31 to 50 ml/min and 1 g q24h for CC of c30 ml/min, while for ceftazidime the adjusted dosage was 2 g ql2h for CC of 31 to 50 ml/min, 2.0 g q24h for CC of 16 to 30 ml/min, and 1 g q24h for CC of -15 ml/min. The minimum length of antibiotic therapy to be considered evaluable for the analysis of efficacy was 4 days, 10 days of therapy was considered standard, and a maximum of 28 days was allowed to achieve a cure. Study drug therapy was terminated upon clinical cure, isolation of a pathogen resistant to cefepime or ceftazidime, poor clinical response, intercurrent illness, or a serious adverse experience considered to be at least possibly related to study drug therapy. Whenever possible, indwelling urinary catheters were removed during study drug therapy for urinary tract infections (UTIs). Subjects were evaluated on study day 3 to 5 and at the RESULTS completion of therapy. Follow-up evaluations (physical examination and microbiology if necessary) were performed 2 There were 112 evaluable subjects; 59 received cefepime weeks following the completion of therapy for all subjects, and 53 received ceftazidime ( there was a resolution of the clinical signs and symptoms of plicated UTI (Table 2) . No subject enrolled in this study had infection, sterilization of the end-of-treatment cultures, and confirmed bacteremia (four of four positive blood cultures).
no need for further antimicrobial therapy prior to follow-up. Cefepime therapy was successful for52p(88%) of 59 subjects, Failure denoted persistence of symptoms, including the need while ceftazidime treatment was successful in 49 (92%) of 53 for further and extensive surgical debnidement during study subjects. Clinical response rates were comparable for skin or drug therapy, persistent or resistant pathogens at the site of wound infections (90% success for cefepime and 94% for infection, or the need for concomitant or additional antibiceftazidime, P = 0.68, Fischer's exact test) and UTIs (84% otic therapy during the protocol or prior to the follow-up for cefepime and 88% for ceftazidime, P = 1.0, Fischer's examination. exact test). As the ceftazidime success rates were uniformly, GENTRY AND RODRIGUEZ-GOMEZ albeit only slightly, higher, type II error analysis was indicated. The statistical powers for the observed differences with this sample size were only 9% for skin or wound infections and 5% for UTIs, the sample sizes needed to achieve 80% power would have been 1,442 and 2,360 subjects, respectively, and the 95% confidence intervals for the differences in cure rates for ceftazidime and cefepime were, respectively, -10 and 19% for skin or wound infections and -24 and 32% for UTIs. Statistical analysis reveals and predicts no differences in the cure rates of cefepime and ceftazidime. Both drugs were well tolerated, with only two mild adverse experiences (increased serum creatinine and diarrhea) in the cefepime group assessed to be at least possibly related to drug therapy. There were no other clinically significant changes observed during the study. No subject failed to receive the minimum 4 days of antibiotic therapy. For three subjects in the cefepime group, the dosage was reduced to 2.0 g q24h because of impaired renal function, with the outcome a clinical cure in all three. One subject in the ceftazidime group received 2.0 g ql2h and was cured.
Three subjects enrolled in the study failed to survive their hospitalization. In the cefepime group, one 85-year-old subject died because of overwhelming sepsis 2 weeks following the completion of an unsuccessful regimen of cefepime for postoperative wound infection due to Proteus mirabilis and Escherichia coli; although these initial pathogens were eradicated; a superinfection due to a cefepime-resistant Enterococcus faecalis strain contributed to the subject's eventual death. One 87-year-old patient was enrolled in the ceftazidime group for surgical wound infection due to Enterobacter cloacae, yet entry cultures subsequently grew a ceftazidimeresistant P. aeruginosa; despite appropriate alternative antibiotic therapy, this patient died 8 days later because of aspiration pneumonia. The other death in the ceftazidime group was due to massive intrapulmonary aspiration of gastric contents 17 days following unsuccessful ceftazidime therapy for UTI due to ceftazidime-susceptible Serratia marcescens.
For the 40 subjects with skin or wound infections who received cefepime, 47 (94%) of 50 pathogens were eradicated, including 9 of 10 P. aeruginosa strains; there were six episodes of superinfection or colonization in this group (Table 3) . Among the 36 subjects with skin or wound infections who received ceftazidime, 39 (95%) of 41 pathogens were eradicated, including five of six P. aeruginosa strains; six episodes of superinfection or colonization accompanied ceftazidime therapy. One persistent P. aeruginosa strain was quantitatively rare, and further antibiotic therapy was not believed to be necessary for the affected subject.
UTIs responded well to each regimen (Table 4 ). In the cefepime group, all 19 initial pathogens were eradicated, whereas 19 (95%) of 20 were eradicated by ceftazidime. Enterococcus faecalis was responsible for a relapse of infection within 4 weeks of the end of drug therapy in one subject in each group, while P. aeruginosa and E. coli were also responsible for relapse in the cefepime group.
Listed in Table 5 are the clinical summaries for the seven subjects for whom therapy with cefepime was not successful, and in Table 6 are listed those four subjects for whom ceftazidime therapy was not successful. Within the important subgroup of diabetic subjects with infections of the skin and skin structure, we note that 9 (82%) of 11 treated with cefepime were cured by the therapy, as opposed to 5 of 5 cured with ceftazidime. For diabetic subjects with UTIs, the response was cure in four (80%) of five treated with cefepime and two of two treated with ceftazidime.
DISCUSSION
From these results, we have an early confirmation in vivo of the results of in vitro and safety studies with cefepime. Cefepime is well tolerated and appears to be comparable to ceftazidime in treatment of skin or wound infections and nosocomial UTIs in hospitalized patients. Although ceftazidime is more active in vitro against P. aeruginosa than cefepime is (2, 5, 7) , clinical and bacteriologic responses for this pathogen were equivalent in this study. Larger studies are required to confirm the relative efficacies of cefepime and ceftazidime in diabetic subjects with infection due to P. aeruginosa.
Cefepime has been shown to have excellent in vitro activity against members of the family Enterobacteriaceae. Strains of Enterobacter spp., S. marcescens, and Citrobacterfreundii which may be resistant to other cephalosporins such as ceftazidime and cefotaxime are frequently very susceptible to cefepime (3, (5) (6) (7) . During the course of this study, one prospective subject was found to have a surgical wound infected with ceftazidime-resistant, cefepime-susceptible Enterobacter cloacae and was compassionately treated for 7 days with cefepime, which effected a cure of the infection. This resistant isolate was in a patient from the Hospital Mexico, San Jose, Costa Rica, study site, where ceftazidime had not been used prior to this study. There is the suggestion that plasmid mediation may not always be responsible for selective resistance to ceftazidime. These data are of great interest to us, as the Enterobacter spp. in our center are usually resistant to available cephalosporins such as ceftazidime. We look forward to further studies to clarify the role of cefepime in treatment of difficult infections due to gram-negative bacteria.
